At the Pacific Brain Health Center in Santa Monica, our experts treat a wide range of neurocognitive conditions that affect the brain such as dementia and Alzheimer’s disease. As these are not curable at this time, clinical trials and research are necessary to develop new and more effective ways of halting and even reversing cognitive decline in these diseases. Find out more in this informative video.
The John Wayne Cancer Institute Auxiliary (JWCIA) honored neurologist and neuro-oncologist Santosh Kesari, MD, PhD, with “The Duke” Special Service Award, and philanthropist and President of Premier Girls Fastpitch Dan Hay with the Generation of Hope Award, at La Odisea, the 34th Odyssey Ball on May 4, 2019. Read more.
The research arm at Pacific Neuroscience Institute confronts some of medicine’s biggest brain tumor challenges. Read this story about glioblastoma and the innovative clinical trial treatment a patient received.
A recently published paper by Pacific Neuroscience Institute researchers suggests a promising new approach for a biopsy-free method to identify primary brain tumor genetics for personalized treatment options.
The Clinical Trials Team at Pacific Neuroscience Institute is pleased to announce a new clinical trial this month for post-stroke shoulder pain. Find out about this and more neurological trails.
Clinical trials using stem cells have shown promising early results as cellular therapies in regenerative medicine, as well as in potential anti-cancer applications. Read more about Dr. Achal Singh Achrol’s neurosurgery clinical trials program and this leading-edge technology.
The neurosciences clinical trials team is pleased to announce two new clinical trials in Overactive bladder and Alzheimer’s disease. Find out more.
Electrical stimulation therapy may have a big impact on brain health and recovery in patients with mood disorders, dementia and neurodegenerative disorders.
Pacific Neuroscience Institute, the leading enrollment site for the MDNA55 clinical trial for Glioblastoma, is still open and enrolling eligible patients. This innovative phase 2 study is for the minimally invasive convection-enhanced delivery (CED) of a new bioengineered targeted therapeutic, MDNA55, in adults with recurrent or progressive glioblastoma. Read more.
Pacific Neuroscience Institute opens up two new clinical trials this month, one in Essential Tremor and one in Glioblastoma. Find out more about these new trials as well as the other available open neurological studies.